美国食品药品监督管理局批准一种通过与无细胞百日咳疫苗复溶组合而成的b型流感嗜血杆菌结合疫苗。
FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine.
出版信息
MMWR Morb Mortal Wkly Rep. 1996 Nov 15;45(45):993-5.
On September 27, 1996, the Food and Drug Administration (FDA) licensed a Haemophilus b Conjugate Vaccine (ActHIB) combined by reconstitution with diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Tripedia) for use as the fourth dose in the childhood vaccination series. This combination vaccine will be sold under the trade name TriHIBit. On July 31, 1996, Tripedia was licensed for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. TriHIBit is the first vaccine to be licensed in the United States that combines DTaP with a Haemophilus b Conjugate Vaccine.
1996年9月27日，美国食品药品监督管理局（FDA）批准了一种B型流感嗜血杆菌结合疫苗（ActHIB），该疫苗通过与白喉和破伤风类毒素及无细胞百日咳疫苗（DTaP）（Tripedia）复溶后联合使用，用作儿童疫苗接种系列的第四剂。这种联合疫苗将以TriHIBit的商品名出售。1996年7月31日，Tripedia被批准用于白喉、破伤风和百日咳疫苗接种系列的初始四剂。TriHIBit是美国批准的第一种将DTaP与B型流感嗜血杆菌结合疫苗联合使用的疫苗。
Zotero 插件